Finally, the integration of CDX2 with molecular biomarkers such as MSI, RAS, BRAF, or SATB2 [27] may lead to the development of comprehensive prognostic and predictive models, supporting a more personalized therapeutic approach in colorectal cancer. The gene discussed is BRAF; the disease is colorectal cancer.